Notice of AGM, Annual Report and Accounts
Summary by AI BETAClose X
Sareum Holdings PLC
(“Sareum” or the “Company”)
Notice of AGM, Annual Report and Accounts
Cambridge, UK, 13 November 2026 – Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that the Company's Annual General Meeting ("AGM") will be held at 10:00 a.m. GMT on Wednesday, 16 December 2026 at the offices of ICR Healthcare, 85 Gresham Street, London EC2V 7NQ.
In order to ensure that shareholders are able to follow the proceedings of the AGM without attending in person, the Company will provide access online via the Investor Meet Company platform. However, please note that shareholders will not be able to vote online at the AGM via the platform and are therefore requested to submit their votes via proxy, as early as possible.
Shareholders that wish to attend the AGM remotely should register for the event in advance by using the following link: https://www.investormeetcompany.com/sareum-holdings-plc/register-investor. Investors who already follow the Company on the Investor Meet Company platform will automatically be invited.
Shareholders are invited to submit any questions for the Board to consider. Questions can be pre submitted ahead of the AGM via the Investor Meet Company Platform up until 15 December 2026, 9:00 a.m. GMT, or submitted at any time during the AGM itself.
Shareholders intending to vote should submit their vote online via the Investor Centre app or at https://uk.investorcentre.mpms.mufg.com/ where details of the procedure are shown. You will need to log into your Investor Centre account or register if you have not previously done so. Once you have setup your account you will need to add your shareholding by clicking ‘Add Holding’ in the ‘Portfolio’ section and following the on-screen instructions. You will require your Investor Code ("IVC") to add your shareholding. You can find your IVC on your share certificate or by contacting our Registrar, MUFG Corporate Markets. If you hold your shares in CREST and wish to vote via the Investor Centre rather than the CREST electronic proxy appointment services please contact our registrars, MUFG Corporate Markets to obtain your Investor Code (via email at shareholderenquiries@cm.mpms.mufg.com or call the registrars’ helpline on 0371 664 0300, calls are charged at the standard geographic rate and will vary by provider; if you are outside the United Kingdom, please call +44 371 664 0300, calls will be charged at the applicable international rate). Alternatively, you may request a paper form of proxy from our registrars.
The notice of AGM, along with a copy of the Company's annual report and accounts for the year ended 30 June 2026, will be posted shortly to those shareholders who requested a hard copy. A copy of both documents will also be available on the Company's website: www.sareum.com in the Investor Relations section.
For further information:
|
Sareum Holdings plc Stephen Parker, Executive Chairman |
01223 497700 ir@sareum.co.uk |
|
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman
Singer Capital Markets (Joint Corporate Broker) Russell Cook/ Patrick Weaver
|
020 7409 3494
020 7496 3000
|
|
Oberon Capital (Joint Corporate Broker) Mike Seabrook / Nick Lovering
|
020 3179 5300 |
|
ICR Healthcare (Financial PR) Jessica Hodgson / Lisa Lam / Tom Daniel |
020 3709 5700 |
About Sareum
Sareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with a planned initial focus on psoriasis.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for certain haematological cancers and has recently initiated a preclinical programme to develop TYK2/JAK1 inhibitors for neuroinflammatory diseases such as multiple sclerosis and Parkinson’s disease.
The Company holds the license for SRA737, a clinical-stage Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company’s website at www.sareum.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund